Clear Search sequence regions


  • antibodies (3)
  • children (1)
  • disease and (1)
  • humans (1)
  • load viral (1)
  • p l (1)
  • vaccines (2)
  • viral load (2)
  • virus (8)
  • Sizes of these terms reflect their relevance to your search.

    In accompanying papers (P. L. Acosta, M. T. Caballero, and F. P. Polack, Clin Vaccine Immunol 23:189-195, 2016, http://dx.doi.org/10.1128/CVI.00609-15; M. Vissers, I. M. L. Ahout, M. I. de Jonge, and G. Ferwerda, Clin Vaccine Immunol 23:243-245, 2016, http://dx.doi.org/10.1128/CVI.00590-15) in this issue of Clinical and Vaccine Immunology, the history of and immune mechanisms underlying vaccine-enhanced respiratory syncytial virus (RSV) disease and of investigations of mucosal antibodies and their association with viral load in RSV-infected children, respectively, are described. This commentary discusses RSV vaccine candidates, target populations, and the challenges associated with achieving a safe and effective vaccine. Copyright © 2016, American Society for Microbiology. All Rights Reserved.

    Citation

    Kathleen M Neuzil. Progress toward a Respiratory Syncytial Virus Vaccine. Clinical and vaccine immunology : CVI. 2016 Mar;23(3):186-8

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 26818954

    View Full Text